Obesity drug Wegovy's landmark trial result could 'open up' health insurance access, analyst says
Publishing timestamp: 2023-08-10 10:52:57
Summary
The weight-loss drug Wegovy may become more widely available under health insurance plans after a successful late-stage trial showed its efficacy in reducing major cardiovascular events. The trial results exceeded expectations, leading analysts to believe that health insurers will be more willing to cover the drug. The trial data could also transform the perception of the drug from a vanity drug to one with health benefits. However, the high cost of the drug and the need for more real-world evidence may still limit widespread coverage. The weight-loss drug industry is projected to be worth $200 billion in the next decade. Novo Nordisk's shares rose significantly following the trial results, and the company may become Europe's most valuable firm by market capitalization. Supply constraints and increased demand may pose challenges for the company in meeting the market's needs.
Sentiment: POSITIVE
Keywords: health care industry, biotechnology, lvmh moet hennessy louis vuitton se, novo nordisk a/s, business news, pharmaceuticals, business, biotech and pharmaceuticals,